SCICLONE PHARMACEUTICALS

SciClone Pharmaceuticals, Inc. (SciClone ) is a global specialty pharmaceutical company. It has a product portfolio of therapies for cancer and infectious diseases. SciClone has in-licensed two products that are part of this international commercial growth strategy, DC Bead and ondansetron RapidFilm. Its DC Bead product candidate is a treatment for liver cancer, which is approved in 40 countries worldwide, including Europe and the United States. Ondansetron RapidFilm is an oral thin film formula... tion of ondansetron used to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy and surgery. SCV-07 is being developed for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck and for the treatment of hepatitis C virus (HCV). Thymalfasin is being developed in an ongoing clinical trial for improvement of Influenza A (H1N1) vaccination.

#SimilarOrganizations #People #Financial #Website #More

SCICLONE PHARMACEUTICALS

Industry:

Biotechnology Health Care

Founded:

1990-01-01

Address:

Foster City, California, United States

Country:

United States

Website Url:

http://www.sciclone.com

Total Employee:

501+

Status:

Active

Contact:

(650) 358-3456

Email Addresses:

[email protected]

Total Funding:

134 M USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible Mobile Non Scaleable Content Euro AJAX Libraries API ASP.NET IIS Sectigo SSL Sectigo Domain SSL ASP.NET 4.0

Similar Organizations

arkuda-therapeutics-logo

Current Advisors List

not_available_image

Li Zhenfu Chairman @ SciClone Pharmaceuticals
Board_member

not_available_image

Jon Saxe Director @ SciClone Pharmaceuticals
Board_member

Current Employees Featured

zhao-hong_image

Zhao Hong
Zhao Hong President and Chief Executive Officer @ SciClone Pharmaceuticals
President and Chief Executive Officer

Founder

not_available_image

Li Zhenfu

Stock Details

Company's stock symbol is HKG:6600

Acquisitions List

Date	Company	Article	Price
2011-04-19	NovaMed Pharmaceuticals	NovaMed Pharmaceuticals acquired by SciClone Pharmaceuticals	105 M USD

Investors List

opportunity-fund_image

Investments List

Date	Company	Article	Money raised
2020-12-28	Ability Pharmaceuticals	SciClone Pharmaceuticals investment in Corporate Round - Ability Pharmaceuticals	3 M USD

Official Site Inspections

http://www.sciclone.com Semrush global rank: 3.38 M Semrush visits lastest month: 4.65 K

Host Informations
Whois Informations

Loading ...